Factors associated with mood disorders and the efficacy of the targeted treatment of functional dyspepsia: A randomized clinical trial
BackgroundPatients with functional dyspepsia (FD) are often accompanied by mood disorders (MDs). This study aimed to identify factors associated with MDs in patients with FD and evaluate the efficacy of targeted treatment plans.MethodsRelevant scales were used to assess MDs. Patients with FD having...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-07-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2022.859661/full |
| _version_ | 1811289185921794048 |
|---|---|
| author | Qian Huang Qian Huang Shaopeng Zheng Shaopeng Zheng Ting Cai Ting Cai Suxin Zhang Suxin Zhang Qian Su Qian Su Fen Wang Fen Wang |
| author_facet | Qian Huang Qian Huang Shaopeng Zheng Shaopeng Zheng Ting Cai Ting Cai Suxin Zhang Suxin Zhang Qian Su Qian Su Fen Wang Fen Wang |
| author_sort | Qian Huang |
| collection | DOAJ |
| description | BackgroundPatients with functional dyspepsia (FD) are often accompanied by mood disorders (MDs). This study aimed to identify factors associated with MDs in patients with FD and evaluate the efficacy of targeted treatment plans.MethodsRelevant scales were used to assess MDs. Patients with FD having MDs and acid reflux were treated with flupentixol and melitracen (FM) and acid-suppressive therapy (AST) (histamine-2 receptor antagonists (H2RAs) (group A) or proton pump inhibitors (PPIs) (group B)), and those without acid reflux (group C) did not receive AST. Patients with FD without MDs were randomly administered H2RAs (group D) or PPIs (group E). The primary endpoints were factors associated with MDs and improvement in gastrointestinal (GI) symptoms and MDs in patients with FD.ResultsA total of 362 patients with FD were enrolled in this study. Patients with FD having high GI score and low education were found prone to MDs. At week 2, the remission rate of overall GI symptoms and depression was significantly higher in group B than that in groups A and C [GI: 72.72% (32/44) vs. 47.73% (21/44) and 72.72% (32/44) vs. 38.94% (44/113), all P < 0.05; depression: 72.22% (26/36) vs. 41.67% (15/36) and 72.22% (26/36) vs. 41.57% (37/89), all P < 0.05]. Furthermore, the remission rate of overall GI symptoms was significantly higher in group E than that in group D [60.29% (41/68) vs. 42.65% (29/68), P < 0.05]. At week 8, similar efficacies and adverse reactions were observed in these groups.ConclusionThe risk factors for MDs were high GI scores and low literacy rates. Thus, targeted treatment (FM+PPIs for patients with MDs; PPIs for patients without MDs) can improve the efficacy of patients with FD.Clinical trial registrationwww.chictr.org.cn, identifier ChiCTR2100053126. |
| first_indexed | 2024-04-13T03:50:26Z |
| format | Article |
| id | doaj.art-b460604b5c824327a05e5ba6fb21768c |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-04-13T03:50:26Z |
| publishDate | 2022-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-b460604b5c824327a05e5ba6fb21768c2022-12-22T03:03:51ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2022-07-01910.3389/fmed.2022.859661859661Factors associated with mood disorders and the efficacy of the targeted treatment of functional dyspepsia: A randomized clinical trialQian Huang0Qian Huang1Shaopeng Zheng2Shaopeng Zheng3Ting Cai4Ting Cai5Suxin Zhang6Suxin Zhang7Qian Su8Qian Su9Fen Wang10Fen Wang11Department of Gastroenterology, The Third Xiangya Hospital, Central South University, Changsha, ChinaHunan Key Laboratory of Non Resolving Inflammation and Cancer, Changsha, ChinaDepartment of Gastroenterology, The Third Xiangya Hospital, Central South University, Changsha, ChinaHunan Key Laboratory of Non Resolving Inflammation and Cancer, Changsha, ChinaDepartment of Gastroenterology, The Third Xiangya Hospital, Central South University, Changsha, ChinaHunan Key Laboratory of Non Resolving Inflammation and Cancer, Changsha, ChinaDepartment of Gastroenterology, The Third Xiangya Hospital, Central South University, Changsha, ChinaHunan Key Laboratory of Non Resolving Inflammation and Cancer, Changsha, ChinaDepartment of Gastroenterology, The Third Xiangya Hospital, Central South University, Changsha, ChinaHunan Key Laboratory of Non Resolving Inflammation and Cancer, Changsha, ChinaDepartment of Gastroenterology, The Third Xiangya Hospital, Central South University, Changsha, ChinaHunan Key Laboratory of Non Resolving Inflammation and Cancer, Changsha, ChinaBackgroundPatients with functional dyspepsia (FD) are often accompanied by mood disorders (MDs). This study aimed to identify factors associated with MDs in patients with FD and evaluate the efficacy of targeted treatment plans.MethodsRelevant scales were used to assess MDs. Patients with FD having MDs and acid reflux were treated with flupentixol and melitracen (FM) and acid-suppressive therapy (AST) (histamine-2 receptor antagonists (H2RAs) (group A) or proton pump inhibitors (PPIs) (group B)), and those without acid reflux (group C) did not receive AST. Patients with FD without MDs were randomly administered H2RAs (group D) or PPIs (group E). The primary endpoints were factors associated with MDs and improvement in gastrointestinal (GI) symptoms and MDs in patients with FD.ResultsA total of 362 patients with FD were enrolled in this study. Patients with FD having high GI score and low education were found prone to MDs. At week 2, the remission rate of overall GI symptoms and depression was significantly higher in group B than that in groups A and C [GI: 72.72% (32/44) vs. 47.73% (21/44) and 72.72% (32/44) vs. 38.94% (44/113), all P < 0.05; depression: 72.22% (26/36) vs. 41.67% (15/36) and 72.22% (26/36) vs. 41.57% (37/89), all P < 0.05]. Furthermore, the remission rate of overall GI symptoms was significantly higher in group E than that in group D [60.29% (41/68) vs. 42.65% (29/68), P < 0.05]. At week 8, similar efficacies and adverse reactions were observed in these groups.ConclusionThe risk factors for MDs were high GI scores and low literacy rates. Thus, targeted treatment (FM+PPIs for patients with MDs; PPIs for patients without MDs) can improve the efficacy of patients with FD.Clinical trial registrationwww.chictr.org.cn, identifier ChiCTR2100053126.https://www.frontiersin.org/articles/10.3389/fmed.2022.859661/fulldyspepsiapsychotropic medicationsPPIsH2RAsefficacy |
| spellingShingle | Qian Huang Qian Huang Shaopeng Zheng Shaopeng Zheng Ting Cai Ting Cai Suxin Zhang Suxin Zhang Qian Su Qian Su Fen Wang Fen Wang Factors associated with mood disorders and the efficacy of the targeted treatment of functional dyspepsia: A randomized clinical trial Frontiers in Medicine dyspepsia psychotropic medications PPIs H2RAs efficacy |
| title | Factors associated with mood disorders and the efficacy of the targeted treatment of functional dyspepsia: A randomized clinical trial |
| title_full | Factors associated with mood disorders and the efficacy of the targeted treatment of functional dyspepsia: A randomized clinical trial |
| title_fullStr | Factors associated with mood disorders and the efficacy of the targeted treatment of functional dyspepsia: A randomized clinical trial |
| title_full_unstemmed | Factors associated with mood disorders and the efficacy of the targeted treatment of functional dyspepsia: A randomized clinical trial |
| title_short | Factors associated with mood disorders and the efficacy of the targeted treatment of functional dyspepsia: A randomized clinical trial |
| title_sort | factors associated with mood disorders and the efficacy of the targeted treatment of functional dyspepsia a randomized clinical trial |
| topic | dyspepsia psychotropic medications PPIs H2RAs efficacy |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2022.859661/full |
| work_keys_str_mv | AT qianhuang factorsassociatedwithmooddisordersandtheefficacyofthetargetedtreatmentoffunctionaldyspepsiaarandomizedclinicaltrial AT qianhuang factorsassociatedwithmooddisordersandtheefficacyofthetargetedtreatmentoffunctionaldyspepsiaarandomizedclinicaltrial AT shaopengzheng factorsassociatedwithmooddisordersandtheefficacyofthetargetedtreatmentoffunctionaldyspepsiaarandomizedclinicaltrial AT shaopengzheng factorsassociatedwithmooddisordersandtheefficacyofthetargetedtreatmentoffunctionaldyspepsiaarandomizedclinicaltrial AT tingcai factorsassociatedwithmooddisordersandtheefficacyofthetargetedtreatmentoffunctionaldyspepsiaarandomizedclinicaltrial AT tingcai factorsassociatedwithmooddisordersandtheefficacyofthetargetedtreatmentoffunctionaldyspepsiaarandomizedclinicaltrial AT suxinzhang factorsassociatedwithmooddisordersandtheefficacyofthetargetedtreatmentoffunctionaldyspepsiaarandomizedclinicaltrial AT suxinzhang factorsassociatedwithmooddisordersandtheefficacyofthetargetedtreatmentoffunctionaldyspepsiaarandomizedclinicaltrial AT qiansu factorsassociatedwithmooddisordersandtheefficacyofthetargetedtreatmentoffunctionaldyspepsiaarandomizedclinicaltrial AT qiansu factorsassociatedwithmooddisordersandtheefficacyofthetargetedtreatmentoffunctionaldyspepsiaarandomizedclinicaltrial AT fenwang factorsassociatedwithmooddisordersandtheefficacyofthetargetedtreatmentoffunctionaldyspepsiaarandomizedclinicaltrial AT fenwang factorsassociatedwithmooddisordersandtheefficacyofthetargetedtreatmentoffunctionaldyspepsiaarandomizedclinicaltrial |